Date:	11/12/2024
Your Name:	Masayuki Bun
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this	Specifications/Comments (e.g., if payments were
		relat	ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present	$\boxtimes$	None	
	manuscript (e.g., funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 month	S
2	Grants or contracts from		None	
	any entity (if not indicated in item #1 above).			
			·	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Takuya Furuichi
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Nam	e all entities with whom you have this	Specifications/Comments (e.g., if payments were
			ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,		None	
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 months	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not			
	indicated in item #1 above).			
	#1 000001.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Hiromasa Hirai
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Nam	e all entities with whom you have this	Specifications/Comments (e.g., if payments were
			ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,		None	
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 months	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not			
	indicated in item #1 above).			
	#1 000001.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Kyoko Hirano
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present		None	
	manuscript (e.g.,	Asa	hi Kasei Pharma Corporation	Employee
	funding, provision of study materials,			Click the tab key to add additional rows.
	medical writing, article processing			
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not indicated in item			
	#1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Masato Ikuta
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Nam	e all entities with whom you have this	Specifications/Comments (e.g., if payments were
			ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,		None	
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 months	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not			
	indicated in item #1 above).			
	#1 000001.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Takashi Kaito
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present		None	
	manuscript (e.g.,	Asa	hi Kasei Pharma	To institution
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing,			
	article processing charges, etc.)			
	No time limit for			
	this item.			
		_	Time frame: past 36 month	S
2	Grants or	$\boxtimes$	None	
	contracts from			
	any entity (if not			
	indicated in item			
	#1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	None Asahi-Kasei Pharma	Takashi Kaito
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Asahi Kasei Pharma	Takashi Kaito
6	Payment for expert testimony	☑     None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑     None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None Asahi Kasei Pharma	To institution
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Takayuki Kitahara
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Nam	e all entities with whom you have this	Specifications/Comments (e.g., if payments were
			ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,		None	
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 months	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not			
	indicated in item #1 above).			
	#1 000001.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Joe Kodama
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Nam	e all entities with whom you have this	Specifications/Comments (e.g., if payments were
			ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,		None	
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 months	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not			
	indicated in item #1 above).			
	#1 000001.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Shinichi Nakagawa
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	None	
	funding, provision		
	of study materials,		Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 month	S
2	Grants or contracts from	None	
	any entity (if not		
	indicated in item		
	#1 above).		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/13/2024
Your Name:	Masahiro Nishida
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present		None	
	manuscript (e.g.,	Asa	hi Kasei Pharma Corporation	Employee
	funding, provision of study materials,			Click the tab key to add additional rows.
	medical writing, article processing			
	charges, etc.) <b>No time limit for</b>			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not indicated in item			
	#1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Seiji Okada
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Nam	e all entities with whom you have this	Specifications/Comments (e.g., if payments were
			ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,		None	
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 months	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not			
	indicated in item #1 above).			
	#1 000001.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/13/2024
Your Name:	Kazuhiro Takeyama
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present		None	
	manuscript (e.g.,	Asa	hi Kasei Pharma Corporation	Employee
	funding, provision of study materials,			Click the tab key to add additional rows.
	medical writing, article processing			
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not indicated in item			
	#1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	11/12/2024
Your Name:	Daisuke Tateiwa
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Nam	e all entities with whom you have this	Specifications/Comments (e.g., if payments were
			ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,		None	
	funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 months	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not			
	indicated in item #1 above).			
	#1 000001.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		ame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/12/2024
Your Name:	Yuichiro Ukon
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this	Specifications/Comments (e.g., if payments were
		relat	ionship or indicate none (add rows as needed)	made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present	$\boxtimes$	None	
	manuscript (e.g., funding, provision			
	of study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 month	S
2	Grants or contracts from		None	
	any entity (if not indicated in item #1 above).			
			·	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		ame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/13/2024
Your Name:	Natsumi Yamamori
Manuscript Title:	Development of a Novel Rat Long-Bone Nonunion Model and Efficacy Evaluation of a Prostaglandin EP4 Selective Agonist (AKDS001) Combined with Iliac Bone Grafting
Manuscript Number (if known):	BJR-2024-0220.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present		None	
	manuscript (e.g.,	Asa	hi Kasei Pharma Corporation	Employee
	funding, provision of study materials,			Click the tab key to add additional rows.
	medical writing, article processing			
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from	$\boxtimes$	None	
	any entity (if not indicated in item			
	#1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑     None	
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Iame all entities with whom you have thisSpecifications/Comments (e.g., if payments wereelationship or indicate none (add rows as needed)made to you or to your institution)
	society, committee or advocacy group, paid or unpaid	
11	Stock or stock options	☑   None     ☑   □     ☑   □     ☑   □
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □     □   □
13	Other financial or non-financial interests	None
Plea	Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form.	